Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report

Yu,Min; Zhang,Shuang; Li,Yanying; Ding,Zhenyu; Peng,Feng

doi:10.3892/ol.2015.3097

Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report

Authors:
- Min Yu
- Shuang Zhang
- Yanying Li
- Zhenyu Ding
- Feng Peng
View Affiliations

Affiliations: Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 2, 2015 https://doi.org/10.3892/ol.2015.3097
Pages: 2874-2878

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cisplatin and gemcitabine regimen is one of the most effective regimens against advanced non-small-cell lung cancer. However, tumors that are initially sensitive to chemotherapy treatment may acquire drug resistance. Excision repair cross complementation 1 gene (ERCC1) is involved in the repair of DNA damage caused by cisplatin, and ribonucleotide reductase M1 subunit (RRM1) is associated with gemcitabine resistance in tumor cells. The current study reports the case of a patient with advanced squamous cell lung carcinoma exhibiting low ERCC1 and RRM1 expression levels, who experienced long‑term survival following repeated responses to gemcitabine and cisplatin chemotherapy. This case indicates that selected patients may benefit from multiple courses of gemcitabine and cisplatin chemotherapy, and the sustained clinical benefits suggest that further investigation into individualized therapy is merited.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ginsberg MS, Grewal RK and Heelan RT: Lung cancer. Radiol Clin North Am. 45:21–43. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 17:1818–1825. 2006. View Article : Google Scholar : PubMed/NCBI
4	Olaussen KA, Dunant A, Fouret P, et al: IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
5	Jao CY and Salic A: Exploring RNA transcription and turnover in vivo by using click chemistry. Proc Natl Acad Sci USA. 105:15779–15784. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tiseo M, Bordi P, Bortesi B, et al: Bio-FAST trial group: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
7	Su C, Zhou S, Zhang L, et al: ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol. 28:1411–1417. 2011. View Article : Google Scholar : PubMed/NCBI
8	Rosell R, Danenberg KD, Alberola V, et al: Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325. 2004. View Article : Google Scholar : PubMed/NCBI
9	Travis WD, Brambilla E and Riely GJ: New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 31:992–1001. 2013. View Article : Google Scholar : PubMed/NCBI
10	Li Y, Wang LR, Chen J, et al: First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. Dis Markers. 960458:20142014.
11	Le Chevalier T, Scagliotti G, Natale R, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 47:69–80. 2005. View Article : Google Scholar : PubMed/NCBI
12	Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
13	National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 4. 2015.
14	Kalemkerian GP, Akerley W, Bogner P, et al: National Comprehensive Cancer Network: Small cell lung cancer. J Natl Compr Canc Netw. 11:78–98. 2013.PubMed/NCBI
15	Khan K, Hanna GG, Campbell L, et al: Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer. Chin J Cancer. 32:539–545. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
17	Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 27:5808–5815. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bepler G, Williams C, Schell MJ, et al: Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wang J, Sun Y and Qin S: Endostar Phase IV Study Group: Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 28:15s2010.
20	Perez-Moreno P, Brambilla E, Thomas R and Soria JC: Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 18:2443–2451. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wu X, Ye Y, Rosell R, et al: Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 103:817–825. 2011. View Article : Google Scholar : PubMed/NCBI
22	Cheng L, Alexander RE, Maclennan GT, et al: Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 25:347–369. 2012. View Article : Google Scholar : PubMed/NCBI
23	Pérez-Soler R: Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene. 28:S38–S45. 2009. View Article : Google Scholar : PubMed/NCBI